Lung Cancer Trial, Recruiting NCT05254782 Sponsor: University Health Network, Toronto Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05254782
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who are able to give written consent to participate
  • People who are generally well enough to carry out daily activities with no or minimal limitations (as measured by a standard cancer health scale called ECOG, with a score of 0 or 1)
  • People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) at certain stages, where the cancer has not spread to lymph nodes or other parts of the body, and where a complete surgical removal of the tumour is planned
  • People whose tumour is at least 1 cm in size and has at least some solid areas visible on a scan
  • People whose removed tumour tissue can be preserved and provided in a standard laboratory format for specialised cancer DNA testing

Who may not be able to join:

  • People who have already received radiation therapy, surgery, or chemotherapy for their current lung cancer diagnosis
  • People whose surgery does not result in complete removal of the tumour
  • People who are currently enrolled in another clinical trial that involves a drug or radiation treatment (participation in observational studies or studies of new surgical methods is allowed)
  • People who currently have another active cancer, or who have had another invasive cancer within the past 2 years (certain non-invasive or early-stage cancers that have been surgically treated, such as some skin cancers, early prostate cancer, cervical carcinoma in situ, or early-stage breast cancer, may not be excluded — confirm with trial site)
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 July 2021
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Rate of ctDNA Detection; Relapse Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov